8.26
price down icon10.70%   -0.99
pre-market  プレマーケット:  7.96   -0.30   -3.63%
loading

Portage Biotech Inc (PRTG) 最新ニュース

pulisher
Mar 30, 2025

Portage Biotech’s After-Hours Surge On Preclinical Tumor Trial Data Sends Retail Optimism Sky-High - Asianet Newsable

Mar 30, 2025
pulisher
Mar 30, 2025

Small Cap Stocks To Add to Your WatchlistMarch 29th - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

Portage Biotech Insider Buyers See Boost After Market Cap Rose US$9.0m - simplywall.st

Mar 30, 2025
pulisher
Mar 30, 2025

Promising Biotech Stocks To Watch Now – March 28th - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Portage Biotech (NASDAQ:PRTG) vs. Cytokinetics (NASDAQ:CYTK) Head-To-Head Survey - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize

Mar 28, 2025
pulisher
Mar 28, 2025

Why Is Portage Biotech Stock Skyrocketing Friday? - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews

Mar 28, 2025
pulisher
Mar 28, 2025

Portage Biotech (PRTG) Shares Skyrocket In Pre-Hour Trading - Stocks Telegraph

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Portage Biotech Shares Jump Premarket After 'Promising' Preclinical Results in Mesothelioma - Marketscreener.com

Mar 28, 2025
pulisher
Mar 27, 2025

Portage Biotech presents preclinical data for PORT-7 - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech reports promising mesothelioma treatment data By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Reports 'Promising' Preclinical Results in Mesothelioma - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech Announces Promising Preclinical Results for PORT-7 in Mesothelioma - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech Reports Promising Preclinical Results In Mesothelioma Supporting First-In-Human Trial Of Port-7 - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech reports promising mesothelioma treatment data - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech stock soars on promising preclinical data - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech stock soars on promising preclinical data By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - The Manila Times

Mar 27, 2025
pulisher
Mar 27, 2025

Game-Changing Mesothelioma Treatment: New Drug Achieves 90% Tumor Reduction in Latest Study - Stock Titan

Mar 27, 2025
pulisher
Mar 13, 2025

Portage Biotech Inc. Announces New Director Compensation Plan and Stock Option Grants - TipRanks

Mar 13, 2025
pulisher
Mar 12, 2025

Portage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6 - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Portage Biotech resumes enrollment in final group of its early-stage study for its cancer treatments - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Portage Biotech Resumes Key Trial Enrollment, Advances Innovative Immunotherapy Approach - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial - The Manila Times

Mar 12, 2025
pulisher
Mar 12, 2025

Major Milestone: Portage Biotech's Novel Cancer Drug Enters Final Trial Phase - StockTitan

Mar 12, 2025
pulisher
Feb 28, 2025

Portage Biotech Stock More Than Doubles On Immunova Deal Potential: Retail Sees Big Opportunity - MSN

Feb 28, 2025
pulisher
Feb 25, 2025

Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange - Newsfile

Feb 25, 2025
pulisher
Feb 16, 2025

Portage Biotech granted Nasdaq compliance extension By Investing.com - Investing.com Nigeria

Feb 16, 2025
pulisher
Feb 14, 2025

Portage Biotech receives extension from Nasdaq to attain listing compliance - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Portage Biotech granted Nasdaq compliance extension - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - The Manila Times

Feb 13, 2025
pulisher
Feb 12, 2025

Portage Biotech Granted Nasdaq Compliance Extension - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

Portage Biotech, Inc. Receives Extension to Regain Nasdaq Compliance Following Acceptance of Compliance Plan - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

Nasdaq Grants Portage Biotech Critical 18-Month Lifeline to Secure Exchange Status - StockTitan

Feb 12, 2025
pulisher
Feb 10, 2025

Hepatocellular Carcinoma Pipeline 2024: Latest FDA Approvals, - openPR

Feb 10, 2025
pulisher
Feb 04, 2025

What is the investor’s view on Portage Biotech Inc (PRTG)? - US Post News

Feb 04, 2025
pulisher
Feb 03, 2025

Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement - Stocks Telegraph

Feb 03, 2025
pulisher
Jan 31, 2025

Portage Biotech Announces Completion of $2.15 Million Private Financing - The Manila Times

Jan 31, 2025
pulisher
Jan 30, 2025

Portage Biotech Secures $2.15 Million in Private Financing - TipRanks

Jan 30, 2025
pulisher
Jan 30, 2025

Portage Biotech, Inc. Completes $2.15 Million Private Placement to Support Corporate Growth - Nasdaq

Jan 30, 2025
pulisher
Jan 30, 2025

Insider Confidence: Portage Directors Invest $2.15M in Strategic Private Placement - StockTitan

Jan 30, 2025
pulisher
Jan 11, 2025

Portage Biotech (NASDAQ:PRTG) Stock Price Down 7.2% – Here’s What Happened - Defense World

Jan 11, 2025
pulisher
Jan 07, 2025

Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc - Marketscreener.com

Jan 07, 2025
pulisher
Jan 06, 2025

Portage Biotech Re-Launches Subsidiary as Cyncado Therapeutics with New CEO - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company - The Manila Times

Jan 06, 2025
pulisher
Jan 06, 2025

Portage Biotech Launches Cyncado Therapeutics to Pioneer Advanced Cancer Immunotherapy Development - StockTitan

Jan 06, 2025
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
大文字化:     |  ボリューム (24 時間):